

# Marcella Callea

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7607704/publications.pdf>

Version: 2024-02-01

17  
papers

653  
citations

1163117

8  
h-index

996975

15  
g-index

17  
all docs

17  
docs citations

17  
times ranked

1806  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hemorrhagic Suprasellar Central Nervous System Embryonal Tumor in an Adult: Uncommon Features of an Extremely Rare Neoplasm. Journal of Neurological Surgery, Part A: Central European Neurosurgery, 2021, , .	0.8	2
2	Pediatric cerebellar pilocytic astrocytoma presenting with spontaneous intratumoral hemorrhage. Neurosurgical Review, 2020, 43, 9-16.	2.4	8
3	Intrathecal rituximab for IgG <sub>4</sub> -related hypertrophic pachymeningitis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 441-444.	1.9	30
4	Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression. Oncotarget, 2017, 8, 103428-103436.	1.8	19
5	Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma. Scientific Reports, 2016, 6, 27702.	3.3	46
6	Association of higher PD-L1 expression in tumor cells of metastatic ccRCC lesions with worse overall survival.. Journal of Clinical Oncology, 2016, 34, e23221-e23221.	1.6	1
7	Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. , 2015, 3, 3.		76
8	Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. Cancer Immunology Research, 2015, 3, 1158-1164.	3.4	237
9	PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. Cancer Immunology Research, 2015, 3, 1308-1315.	3.4	114
10	Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer. Clinical Cancer Research, 2015, 21, 1925-1934.	7.0	67
11	PD-L1 expression in mononuclear cells and not in tumor cells, correlated with prognosis in metastatic urothelial carcinoma.. Journal of Clinical Oncology, 2014, 32, 4552-4552.	1.6	2
12	PD-L1 expression in primary clear cell renal cell carcinomas (ccRCCs) and their metastases.. Journal of Clinical Oncology, 2014, 32, 4585-4585.	1.6	5
13	PD-L1 expression in non-clear cell renal cell carcinoma.. Journal of Clinical Oncology, 2014, 32, 424-424.	1.6	5
14	PD-L1 expression in primary clear cell renal cell carcinomas (ccRCCs) and their metastases.. Journal of Clinical Oncology, 2014, 32, 467-467.	1.6	13
15	PD-L1 expression in non-clear cell renal cell carcinoma and benign kidney tumors.. Journal of Clinical Oncology, 2014, 32, 4526-4526.	1.6	1
16	<i>HER2</i> amplification status in gastric and gastroesophageal junction cancer in routine clinical practice: which sample should be used?. Histopathology, 2012, 61, 134-135.	2.9	6
17	Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma. Oncotarget, 0, 7, 41857-41869.	1.8	21